Nanosystems and Antibody/Peptide Modified Drugs for Cancer Treatment
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: 20 September 2024 | Viewed by 1313
Special Issue Editors
Interests: natural products; alkaloids; terpenes; plant extracts; synthesis of organic compounds; chemical modification of drugs; organic materials: synthesis and nanostructuration of surfaces; nanoparticles for drug delivery; polymers and applications
Special Issues, Collections and Topics in MDPI journals
Interests: natural products; bioactive compounds; total synthesis; antitumor; antibiotics; cyclodepsipeptides; cyclopeptides
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Currently, the first line of treatment in cancers is the surgical removal of solid tumors. After primary surgical resection, the main action includes the intravenous administration of systemic chemotherapy treatments using cytotoxic molecules. However, after that, an important drawback is tumor recurrences caused by cancer cells that evade primary treatment and are incorporated into the blood stream, causing a high number of deaths due to metastasis. Furthermore, current chemotherapy treatments reach toxic levels that damage healthy cells, causing serious side effects such as infection, bleeding and anemia, peripheral neuropathy (pain), allergic reactions, mucositis, and diarrhea, among others, represent a serious limitation and lead to therapy failure. In addition, a specific applied chemotherapeutic treatment may be ineffective due to multidrug resistance (MDR), caused by the resistance of some remaining cancer cells due to the lack of a specific targeting. Finally, their systemic and (therefore not localized) administration represents a great disadvantage since these molecules cannot be administered in low doses and/or gradually. Consequently, it is necessary to discover and develop new chemical formulations capable of improving their antitumor efficiencies in terms of activity and selectivity, compared with conventional chemotherapeutic drugs, currently approved for cancer therapy.
In this context, it is necessary to develop new systems and cytotoxics that increase direct activity on tumor cells and reduce the drug concentration to which the patient is exposed to avoid secondary effects. The Topic presented here aims to solve specific problems associated with cancer recurrence through the development of new antibody/peptide derivatives and analogues with higher antitumor activity, low unwanted secondary effects and better viability compared with the current chemotherapeutic drugs.
Prof. Dr. Juan Manuel López Romero
Prof. Dr. Francisco Sarabia
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody
- peptide
- vectorized drugs
- nanocarriers
- engineered drugs
- improved drug delivery
